Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline

Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target class Initial discovery pipeline focused on high-value

Related Keywords

California ,United States ,Netherlands ,San Carlos ,Matt Crenson ,Nancy Pryer ,Scott Clarke ,Melissa Mccracken ,Michelle Arkin ,Kostenloser Wertpapierhandel ,Adam Rosenberg ,Christian Ottmann ,Luc Brunsveld ,Director Of The Small Molecule Discovery Center ,Eindhoven University Of Technology ,Mission Biocapital ,Ventures Fund ,Droia Ventures ,Inkef Capital ,Abbvie Ventures ,Surveyor Capital ,Pharmaceutical Chemistry ,Small Molecule Discovery Center ,Chemical Biology ,Eindhoven University ,Associate Professor ,Molecular Cell ,Structural Biology ,Chief Executive Officer Scott Clarke ,Tizona Therapeutics ,Trishula Therapeutics ,Chief Scientific Officer Nancy Pryer ,Day One Biopharmaceuticals ,Chief Development Officer ,Ambagon Therapeutics ,Modular Ambagon Drug Discovery Platform ,Bridge Communications ,Ambagon ,Herapeutics ,Aunches ,Ith ,Billion ,Series ,Advance ,Ioneering ,Olecular ,Blue ,Platform ,Progress ,Pipeline ,